A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Study of SAGE-324 for the Treatment of Essential Tremor
Latest Information Update: 04 Oct 2024
At a glance
- Drugs SAGE-324 (Primary)
- Indications Essential tremor
- Focus Therapeutic Use
- Acronyms KINETIC 2
- Sponsors Sage Therapeutics
- 26 Sep 2024 According to Sage Therapeutics media release, Sage Therapeutics announces discontinuation of the collaboration with Biogen on the SAGE-324 program, The companies recently announced negative results from the Phase 2 KINETIC 2 Study of investigational SAGE-324 for the chronic treatment of essential tremor (ET) and discontinued further clinical development of SAGE-324 in ET.
- 24 Jul 2024 Primary endpoint (Change From Baseline in The Essential Tremor Rating Assessment Scale (TETRAS) Performance Subscale Item 4 (Upper Limb) Total Score on Day 91 in the Monotherapy Cohort) has not been met as per Sage Therapeutics Media Release.
- 24 Jul 2024 Results published in the Sage Therapeutics Media Release